低剂量阿糖胞苷预防唐氏综合征患儿髓系白血病:TMD预防2007研究
这项多中心、非随机、历史对照的TMD预防2007试验评估低剂量阿糖胞苷对暂时性骨髓增殖性疾病(TMD)患儿生存及预防髓系白血病(ML-DS)的影响。102例入组TMD患者的5年无事件生存率和总生存率分别为72±5%和91±3%。有症状患者中,治疗组早期死亡累积发生率显著低于历史对照组(12±5% vs 33±7%,PGray=.02),但治疗未能显著降低ML-DS累积发生率(25±7% vs 14±7%,PGray=.34)。
要点
- 低剂量阿糖胞苷可降低有症状TMD患者的早期死亡累积发生率(12±5% vs 历史对照33±7%,PGray=.02)。
- 治疗未能显著降低ML-DS累积发生率(治疗组25±7% vs 未治疗组14±7%,PGray=.34)。
- 无症状TMD患者本研究中无一例发生早期死亡。
核心结论
- 低剂量阿糖胞苷治疗与历史对照相比有助于降低TMD相关死亡,但不足以预防进展为ML-DS。
研究设计与样本
- 多中心、非随机、历史对照的TMD预防2007试验,共入组102例TMD患者。
- 在诊断时存在TMD相关症状(高白细胞计数、腹水、肝功能障碍、胎儿水肿)或诊断后8周检测到微小残留病(MRD)时给予阿糖胞苷1.5 mg/kg,持续7天。
主要发现
- 102例入组TMD患者的5年无事件生存率和总生存率分别为72±5%和91±3%。
- 因症状符合治疗条件的患者(n=43)与历史对照中有症状患者(n=45)相比,早期死亡累积发生率显著更低(12±5% vs 33±7%,PGray=.02)。
- 本研究中无症状患者无一例发生早期死亡。
- 有症状或MRD阳性患者的治疗未显著降低ML-DS累积发生率(治疗组25±7% vs 未治疗组14±7%,PGray=.34,按方案分析;历史对照22±4%,PGray=.55)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 5% to 10% of children with Down syndrome (DS) are diagnosed with transient myeloproliferative disorder (TMD). Approximately 20% of these patients die within 6 months (early death), and another 20% to 30% progress to myeloid leukemia (ML-DS) within their first 4 years of life. The aim of the multicenter, nonrandomized, historically controlled TMD Prevention 2007 trial was to evaluate the impact of low-dose cytarabine treatment on survival and prevention of ML-DS in patients with TMD. Patients received cytarabine (1.5 mg/kg for 7 days) in case of TMD-related symptoms at diagnosis (high white blood cell count, ascites, liver dysfunction, hydrops fetalis) or detection of minimal residual disease (MRD) 8 weeks after diagnosis. The 5-year probability of event-free and overall survival of 102 enrolled TMD patients was 72 ± 5% and 91 ± 3%, respectively. In patients eligible for treatment because of symptoms (n = 43), we observed a significantly lower cumulative incidence (CI) of early death as compared with symptomatic patients in the historical control (n = 45) (12 ± 5% vs 33 ± 7%, PGray = .02). None of the asymptomatic patients in the current study suffered early death. However, the treatment of symptomatic or MRD-positive patients did not result in a significantly lower CI of ML-DS (25 ± 7% [treated] vs 14 ± 7% [untreated], PGray = .34 [per protocol analysis]; historical control: 22 ± 4%, PGray = .55). Thus, low-dose cytarabine treatment helped to reduce TMD-related mortality when compared with the historical control but was insufficient to prevent progression to ML-DS. This trial was registered at EudraCT as #2006-002962-20.
引用
- Flasinski M, Scheibke K, Zimmermann M, et al. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Adv. 2018. PMID: 29959152. doi:10.1182/bloodadvances.2018018945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。